Asia-Pacific journal of clinical oncology最新文献

{"title":"Enhancing Diagnostic Precision in Breast Cancer Detection: A Digital Breast Tomosynthesis Workshop Approach for Clinicians in the Southeast Asian Population.","authors":"Phuong Dung Yun Trieu, Oanh Tm Tran, Garvin Williamsz, Lam Le Ngo, Linh Thuy Nguyen, Due T Ong, Hao Thi Nguyen, Jenny O'Sullivan, Jillian Clarke, Melissa L Barron, Dania Abu Awwad, Sarah J Lewis","doi":"10.1111/ajco.70033","DOIUrl":"https://doi.org/10.1111/ajco.70033","url":null,"abstract":"<p><strong>Background: </strong>This study investigated the impact of Digital Breast Tomosynthesis (DBT) training workshops on doctors' performance in simultaneous-double-reader scenarios.</p><p><strong>Methods: </strong>Ten pairs of Vietnamese readers, including radiologists, registrars, and breast physicians, participated in the workshop, which featured lectures and breast image reading sessions provided by Australian experts. The first session included a test set of 30 screening full-field digital mammograms (FFDM) (10 cancers and 20 normal cases) with DBT images provided during the answer review stage. The second session with 35 cases (15 cancer) and session 3 with 30 cases (11 cancer) consisted of screening FFDM mammograms, DBT slices, and synthesized images. Participants used the BREAST-VIETRAD platform to view breast images and detect cancer lesions using the RANZCR-BIRADS scale. The study assessed performance disparities between the first and second DBT sets using the Wilcoxon Signed Rank test and explored the correlation between score changes and reader experience.</p><p><strong>Results: </strong>There were significant improvements in the readers' sensitivity (0.553 vs. 0.91; p = 0.005) and lesion sensitivity (0.419 vs. 0.709; p = 0.005) from the first to the second DBT set, matching the sensitivity seen in FFDM sets. This improvement was consistent across both low and high breast density cases. Notable enhancements in lesion sensitivity were also observed for detecting masses (0.340 vs. 0.633; p = 0.011), calcifications, and architectural distortions (0.450 vs. 0.933; p = 0.011). The probability of score improvement (ROC AUC and JAFROC FOM) in DBT of pairs of readers with both less than 3 years of experience in reading mammograms is five times greater than those with over 5 years of experience.</p><p><strong>Conclusions: </strong>Training sessions with simultaneous-double readers significantly improved Vietnamese clinicians' breast cancer detection capabilities, highlighting the importance of tailored educational programs to enhance diagnostic accuracy in regions lacking formal screening initiatives.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145228376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Outcomes of Patients Treated With Neoadjuvant Imatinib for Locally Advanced, Recurrent and Limited Metastatic Gastrointestinal Stromal Tumour in an Australian Cancer Training Network.","authors":"Amy E Smith, Karan Gupta, Florian Honeyball, Peter Grimison, Philip Beale","doi":"10.1111/ajco.70034","DOIUrl":"https://doi.org/10.1111/ajco.70034","url":null,"abstract":"<p><strong>Background: </strong>Imatinib for palliative and adjuvant treatment of gastrointestinal stromal tumours (GISTs) with common KIT mutations has been revolutionary. For patients with locally advanced, limited metastatic or recurrent disease, neoadjuvant imatinib may downstage the tumour, enabling surgery with curative intent; however, the optimal duration of neoadjuvant imatinib is unknown.</p><p><strong>Methods: </strong>We conducted a retrospective review of patients with locally advanced, limited metastatic and recurrent GIST treated with neoadjuvant imatinib prior to consideration of surgical resection in the period 2012-2024 at three cancer centres in NSW, Australia. Baseline and outcome data were collected. The primary endpoint was the progression-free survival (PFS).</p><p><strong>Results: </strong>A total of 30 patients were identified with 38 instances of primary locally advanced, recurrent or limited metastatic disease. The median per-patient duration of neoadjuvant imatinib was 7.8 months (range 2.9-14.9 months), and the median per-episode duration of neoadjuvant imatinib was 9.1 months (range 3.0-27.4 months). Maximum radiological response was achieved at 3.8 months for primary tumours and 6.7 months for recurrent tumours. Partial response occurred in 77% and progression in 0%. Of the 25 patients with available data, 96% were symptomatic, and 89% reported early symptomatic benefit from imatinib within 1 month. Complete surgical resection occurred in 58% of all episodes of neoadjuvant treatment. The estimated PFS rates at 2 and 5 years were 84% and 55% respectively. Overall survival rates were 84% at both 2 and 5 years.</p><p><strong>Conclusions: </strong>Neoadjuvant imatinib provided effective symptomatic and radiological responses in patients with locally advanced, limited metastatic or recurrent GIST. A duration of 3-6 months treatment for primary tumours and 6-12 months for recurrent disease appears sufficient for most patients. Mutational profile analysis is of particular value for patients who do not have early symptomatic benefit, have poor radiological response or have recurrent disease.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Factors of Coronavirus Disease 2019 In-hospital Mortality in Cancer Patients: A Retrospective Cohort Study in Taiwan.","authors":"Jing-Gu Jiang, Shih-Chiang Lin, Jia-Hao Zhang, Yun-Sung Chen, Cheng-Hung How, Yuan-Bin Yu, Hou-Tai Chang","doi":"10.1111/ajco.70032","DOIUrl":"https://doi.org/10.1111/ajco.70032","url":null,"abstract":"<p><strong>Aim: </strong>The coronavirus disease 2019 (COVID-19) pandemic has significantly strained global healthcare systems. Cancer patients are particularly vulnerable to adverse outcomes from COVID-19 infection. The aim of this study is to determine adverse prognostic factors in Taiwanese cancer patients who contract COVID-19.</p><p><strong>Methods: </strong>This retrospective cohort study reviewed the medical records of patients with cancer who were admitted for a COVID-19 infection to a tertiary medical center in Taipei from 2020 to 2022 were retrospectively reviewed. The study endpoint was all-cause mortality during hospitalization. Cox regression analyses using the stepwise selection method were used to determine factors associated with survival, which included patient demographic characteristics, medical history, length of intensive care unit (ICU) stay, presence of fever at admission, microbial culture results, vaccination status, cancer types, and laboratory metrics.</p><p><strong>Results: </strong>Forty-two patients were included in the analyses, of which 20 died. The mean age of the patients was 71 years. Stepwise regression analyses identified the following factors were risk factors for worse survival: presence of fever at admission (hazard ratio [HR] = 9.31, 95% confidence interval [CI]: 2.38-36.42, p = 0.001), higher Acute Physiology and Chronic Health Evaluation (APACHE) II score (HR = 1.13, 95% CI: 1.05-1.23, p = 0.002), higher total bilirubin (HR = 1.15, 95% CI: 1.05-1.26, p = 0.004), and higher creatinine level (HR = 1.38, 95% CI: 1.16-1.64, p < 0.001). Higher neutrophil segment percentage and blood urea nitrogen levels showed marginally significant associations with survival.</p><p><strong>Conclusions: </strong>Factors associated with worse survival in cancer patients who contract COVID-19 are fever at admission, high APACHE II score, and elevated levels of total bilirubin and creatinine.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145190766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole Brain Radiotherapy Versus Stereotactic Radiosurgery in Breast Cancer Patients With Brain Metastases-A Phase 3 Open Label Randomized Study.","authors":"Budhi Singh Yadav, Porva Vias, Ngangom Robert, Venkata Krishna Vamsi Gade, Aashima Kajla","doi":"10.1111/ajco.70029","DOIUrl":"https://doi.org/10.1111/ajco.70029","url":null,"abstract":"<p><strong>Background: </strong>Patients with brain metastases can be treated with whole-brain radiotherapy (WBRT) or stereotactic radiosurgery (SRS). There are no randomized study comparing WBRT with SRS in patients with brain metastases from breast cancer. This study aimed to compare WBRT with SRS in patients with breast cancer with brain metastases.</p><p><strong>Material and methods: </strong>Breast cancer patients with 1-5 brain metastases, ≤ 3.5 cm and KPS ≥ 60 were randomized to WBRT or SRS. WBRT dose was 30 Gy/10 fractions /2 weeks. SRS dose varied from 18 to 24 Gy per fraction to 27-36 Gy in 3-6 fractions. Primary endpoint was overall survival (OS) and the secondary end points were progression free survival (PFS), performance and neurologic status, and cognitive impairment. The trial was approved by the institute ethics committee and registered in clinicaltrials.gov NCT05144867.</p><p><strong>Results: </strong>Between July 2021 and January 2023, 103 patients were randomized; 51 in the WBRT arm and 52 in the SRS arm. Mean tumor diameter was 3.40 ± 1.22 and 2.81 ± 1.24 cm in WBRT and SRS, respectively. The median follow-up duration was 17.5 months (IQR- 7-21.9 months). Local recurrences were observed in five (9%) and nine (17%) patients in the WBRT and SRS (p = 0.32) group, respectively. Distant intracranial relapse occurred in 11 (21%) and 20 (39%) patients treated with WBRT and SRS (p = 0.36), respectively. Median OS was 17.4 months (95% CI: 6.63-17.8 months) in the WBRT arm and 14.6 months (95% CI: 14-15.2 months) in the SRS arm (p = 0.817). Median PFS was 13.9 and 11.0 months, respectively, for WBRT and SRS (p = 0.73). The 1-year OS and PFS were 55% and 47% (p = 0.51) and 41% and 43% (p = 0.75) with WBRT and SRS, respectively. At 3 months, patients treated with WBRT showed significantly better improvement in KPS (p = 0.004). In both the arms the MMSE improved at 3 months from the baseline, but it was greater with SRS.</p><p><strong>Conclusion: </strong>There was no significant difference in the outcomes between the SRS and WBRT in breast cancer patients with brain metastasis. WBRT led to a significant improvement in the KPS. Cognitive decline was lower in the SRS arm.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145124045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility of Clinically Prioritized Colorectal Cancer Quality Indicators With a New South Wales Population-Based Linked Dataset.","authors":"Candice Donnelly, Puma Sundaresan, James Toh, Gabriel Gabriel, Tim Shaw, Anna Janssen, Paul Harnett, Shalini Vinod","doi":"10.1111/ajco.70016","DOIUrl":"https://doi.org/10.1111/ajco.70016","url":null,"abstract":"<p><strong>Aim: </strong>To determine the feasibility of using population-based linked data to measure an Australian multidisciplinary set of 26 colorectal cancer (CRC) quality indicators.</p><p><strong>Methods: </strong>Data were obtained on adult patients diagnosed with CRC (ICD-10-AM codes C18-C20) between July 1, 2005 and December 31, 2019 from the New South Wales (NSW) Cancer Registry. The NSW Cancer Registry data were linked to the Clinical Cancer Registry, Admitted Patient Data Collection, and death records. The feasibility assessment included (1) mapping required variables to available data, (2) review of publicly available reports to identify routine reporting of the indicators, (3) assessment of data completeness and coverage using proportional analyses, and (4) pilot test calculation of feasible indicators where data exist.</p><p><strong>Results: </strong>Data mapping found that 14 indicators were potentially feasible. Linked data were available for 38,430 patients to test eight surgical indicators and 8489 patients to test six neoadjuvant therapy indicators. The data required to measure these indicators had significant limitations in data coverage, completeness, and quality, rendering the calculations unreliable and some implausible. The data completeness for staging ranged from 74% to 85%, and almost one half of diagnosis dates were illogical. Overall, six of the 26 indicators were feasible and reliable to measure. These addressed unplanned reoperation/readmission, colonoscopy, surgical mortality, and survival.</p><p><strong>Conclusion: </strong>This study identified six clinically relevant quality indicators feasible to measure using NSW population-based data. However, these indicators were surgical processes and outcomes. There are insufficient data to produce adequate and clinically meaningful quality measurements for a multidisciplinary CRC team, particularly in diagnostic workup, neoadjuvant therapy, and supportive care.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145074269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to \"Epirubicin May Enhance the Inhibition of Hepatocellular Carcinoma Induced by Iodine-125 Seeds Through Downregulating WNT Pathway\".","authors":"","doi":"10.1111/ajco.70013","DOIUrl":"https://doi.org/10.1111/ajco.70013","url":null,"abstract":"","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145028844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does Limited-Margin Radiotherapy Change the Recurrence Pattern and Survival of Patients With IDH-Wild-Type Glioblastoma? Analysis and Validation of a Different Approach.","authors":"Volkan Semiz, Oguz Cetinayak, Barbaros Aydın, Seyda Kınay, Dogukan Akcay, Nuri Karabay, Fadime Akman Can","doi":"10.1111/ajco.70014","DOIUrl":"https://doi.org/10.1111/ajco.70014","url":null,"abstract":"<p><strong>Purpose: </strong>We aimed to analyze our radiotherapy protocol by evaluating its effect on recurrence patterns and survival outcomes.</p><p><strong>Methods: </strong>We assessed 69 patients diagnosed with IDH-wild-type glioblastoma who underwent chemoradiotherapy at our institution from January 2014 to January 2021. A high-risk clinical target volume (CTV_high) was created with a 1 cm margin in all directions from the GTV, while a low-risk clinical target volume (CTV_low) was established with a 2 cm margin. Planned treatment volumes with a 2-3 mm margin in all directions were created, and doses of 60 and 50 Gy were prescribed in 30 fractions. Recurrence patterns were classified as central, in-field, marginal, or distant based on the 60 and 50 Gy D95 isodose lines.</p><p><strong>Results: </strong>With a median follow-up of 21 months, 88.4% of patients experienced recurrence. The overall survival rates at 1, 2, and 5 years were 84.1%, 51.5%, and 17%, respectively. The progression-free survival rates at the same intervals were 44.9%, 21.5%, and 9.5%, respectively. Recurrence patterns were central in 63.9%, in-field in 18%, marginal in 4.9%, and distant in 13.1%.</p><p><strong>Conclusion: </strong>The recurrence pattern remained unchanged with our protocol. With longer survival times, distant recurrence rates increase, yet central and in-field recurrences remain dominant. Despite the decrease in the volume that received the 60 Gy dose, marginal recurrences remained at a notably low level.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145028873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hematological Markers Predict Immune-Related Adverse Events in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Pembrolizumab.","authors":"Takashi Matsuki, Takuro Okada, Chihiro Fushimi, Hideaki Takahashi, Isaku Okamoto, Takahito Kondo, Kunihiko Tokashiki, Kenji Hanyu, Takuma Kishida, Tatsuya Ito, Gai Yamashita, Kiyoaki Tsukahara, Tatsuo Masubuchi, Yuichiro Tada, Kaho Momiyama, Yukiko Asako, Kohei Hagiwara, Hidetaka Ikemiyagi, Ryohei Yaguchi, Nobuhiko Oridate, Go Omura, Taku Yamashita","doi":"10.1111/ajco.70012","DOIUrl":"https://doi.org/10.1111/ajco.70012","url":null,"abstract":"<p><strong>Background: </strong>In patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), the correlation between hematological markers and treatment outcomes has been established. However, their predictive role in the development of immune-related adverse events (irAEs) remains unclear.</p><p><strong>Methods: </strong>We conducted a multicenter retrospective cohort study to evaluate whether pre-treatment hematological markers-including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and the CRP-albumin-lymphocyte (CALLY) index-predict the development of irAEs in 147 patients with R/M SCCHN treated with pembrolizumab.</p><p><strong>Results: </strong>Lower NLR and PLR, as well as higher LMR and CALLY index, were significantly associated with a higher incidence of irAEs. Furthermore, NLR and LMR were significantly correlated with the occurrence of severe (Grade ≥ 3) irAEs.</p><p><strong>Conclusion: </strong>Pre-treatment NLR, PLR, LMR, and CALLY index may serve as useful predictive markers for the development of irAEs in patients with R/M SCCHN treated with pembrolizumab.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145013829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy Assessment of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane: An Open-Label, Single-Arm, Phase IV Study.","authors":"Sudeep Gupta, Manish Singhal, Shona Nag, Waseem Abbas, Dinesh Chandra Doval, Hari Goyal, Chirag Shah, Ashish Singh, Radheshyam Naik, Nitesh Rohatgi, Poonam Patil, Shyam Aggarwal, Vinod Raina, Vaibhav Watts","doi":"10.1111/ajco.70007","DOIUrl":"https://doi.org/10.1111/ajco.70007","url":null,"abstract":"<p><strong>Introduction: </strong>Trastuzumab emtansine (T-DM1), an antibody-drug conjugate, targets tumor cells overexpressing human epidermal growth factor receptor 2 (HER2). This single-arm, phase IV study assessed the safety and efficacy of T-DM1 in Indian patients with HER2-positive, locally advanced, or metastatic breast cancer previously treated with trastuzumab and a taxane.</p><p><strong>Methods: </strong>Patients received T-DM1 (3.6 mg/kg intravenously every 3 weeks) until death, disease progression, unacceptable toxicity, consent withdrawal, or up to a maximum of 12 months after the last patient's first visit, whichever occurred first. Safety was mainly assessed by the incidence and severity of adverse events (AEs). Efficacy was evaluated by progression-free survival (PFS), overall survival (OS), and overall response rate (ORR). Patients were followed up posttreatment until 12 months or until lost to follow-up, withdrawn consent, or death.</p><p><strong>Results: </strong>A total of 70 eligible patients (median age [range]: 50.0 [27.0-75.0] years) received at least one dose of T-DM1 (median duration [range]: 32.0 [1.0-125.0] weeks). Adverse events in 21 (30.0%) patients were treatment-related. The most common treatment-related AEs and SAEs were thrombocytopenia (seven [10.0%] and three [4.0%] patients, respectively) and epistaxis (four [6.0%] and two [3.0%] patients, respectively). During the study, 10 (18.0%) patients died (disease progression: n = 6; AE: n = 3; and unknown reason: n = 1), while 2 patients died during the follow-up period. Median PFS was 14 months (95% confidence interval [CI]: 8.0, 17.0). Among 65 evaluable patients, 16 (23.0%) achieved partial responses; ORR was 23.0%.</p><p><strong>Conclusions: </strong>Trastuzumab emtansine was found to be safe and efficacious in the Indian patients.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145013831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"USP44, ZNF454, and GPRC5B ctDNA Methylation Markers in Breast Cancer: Limited Clinical Relevance for Disease Monitoring and Tumor Characteristics.","authors":"Young Ju Jeong, Chang-Ho Jeon, Hoon Kyu Oh, Jeong Kyu Kim, Chun-Seok Yang, Na-Rang Lee, Doyeon Kim","doi":"10.1111/ajco.70015","DOIUrl":"https://doi.org/10.1111/ajco.70015","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to identify breast cancer-specific circulating tumor DNA (ctDNA) methylation markers that correspond to tissue DNA methylation.</p><p><strong>Methods: </strong>Using The Cancer Genome Atlas (TCGA) database, we selected breast cancer-specific DNA methylation markers. The methylation and expression patterns of candidate genes were analyzed in breast cancer cell lines and tissue samples. We also assessed the methylation status in ctDNA obtained from breast cancer patients and examined associations with the clinicopathological features.</p><p><strong>Results: </strong>Among candidate genes with breast cancer-specific methylation patterns, USP44, ZNF454, and GPRC5B were selected. The methylation status and expression of selected genes varied by molecular subtype of cancer in the cell line. In tissue samples, expression of all three genes was generally lower in breast cancer than in controls. ctDNA methylation patterns showed no significant change before and after treatment for each candidate gene. Correlations between gene expression and DNA methylation status or clinicopathological characteristics in cancer tissues differed among genes.</p><p><strong>Conclusion: </strong>Further studies are needed for clinical application of liquid biopsy using methylation analysis for ctDNA according to individual characteristics for breast cancer.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145022803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}